Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
Safety endpoint met, with encouraging signs of efficacy in trial with 23…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
